Press releases

26 February, 2021
News
IR
English
Corporate Information
Other Corporate Information
As part of Ziccum’s strategy of actively reaching out to global vaccine policymakers worldwide, Ziccum CEO Göran Conradson has submitted formal feedback to the EU’s consultation for the European Health Emergency Preparedness and Response...
11 February, 2021
News
IR
English
Regulatory
Listing Regulation
Report
Interim
Yearend
Summary of year-end report, fourth quarter 2020 During the fourth quarter, Ziccum announced that it had carried out a pilot study on large-scale production of temperature-stable vaccines. The pilot study centred on a Fill and Finish facility (the last...
11 February, 2021
News
IR
Swedish
Regulatory
Listing Regulation
Report
Interim
Yearend
Sammanfattning av delårsrapporten - fjärde kvartalet 2020 Under fjärde kvartalet meddelade Ziccum att en pilotstudie på storskalig produktion av temperaturstabila vacciner har genomförts. Pilotstudien avser en Fill and finish-anläggning...
25 January, 2021
News
IR
English
Regulatory
MAR
Corporate Action
Other
Lund, January 25, 2021 -- Ziccum AB (publ) (‘Ziccum’) entered into an evaluation study agreement on 3 Oct 2019 with Janssen Vaccines & Prevention B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Based on positive...
25 January, 2021
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
Lund, 25 januari 2021. Ziccum AB (publ) (‘Ziccum’) ingick ett utvärderingsavtal 3 oktober 2019 med Janssen Vaccine & Prevention B.V., en av Janssens läkemedelsbolag som tillhör Johnson & Johnson. Baserat på de...
12 January, 2021
News
IR
Swedish
Corporate Action
Other
Lund, 12 januari 2021. Ziccums huvudmål för 2021 är att ingå Bolagets första licensavtal, samt att presentera en detaljerad plan för att etablera en produktionsanläggning för fyllning och slutförpackning...
12 January, 2021
News
IR
English
Corporate Action
Other
Lund, 12 January 2021. Ziccum's major goals for 2021 are to enter into its first licensing agreement for a dry-formulated vaccine, and to present a detailed plan for establishing a Fill and Finish production facility for the filling and final packaging...
01 December, 2020
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Action
Other
Ziccum AB (”Ziccum” eller ”Bolaget”) meddelar att handeln av Bolagets aktie på Nasdaq First North Growth Market inleds i dag under kortnamn ”ZICC” med ISIN SE0011415595. Göran Conradson, VD, kommenterar...
16 November, 2020
News
IR
English
Regulatory
Listing Regulation
Corporate Action
Other
Ziccum AB will be delisted from Spotlight after close of the market on November 30, 2020. For more information, see the press release from the company. Information about the share: Shortname: ZICC ISIN-code: SE0011415595 Orderbook-ID: 4NG9 CFI...
11 November, 2020
News
IR
English
Regulatory
LHFI
Corporate Action
Other
Ziccum AB ("Ziccum" or "the Company") announces today, November 11, 2020, that it has received approval for admission to trade on the Nasdaq First North Growth Market. The first day of trading on the Nasdaq First North Growth Market...
11 February, 2021
News
IR
English
Regulatory
Listing Regulation
Report
Interim
Yearend
Summary of year-end report, fourth quarter 2020 During the fourth quarter, Ziccum announced that it had carried out a pilot study on large-scale production of temperature-stable vaccines. The pilot study centred on a Fill and Finish facility (the last...
11 February, 2021
News
IR
Swedish
Regulatory
Listing Regulation
Report
Interim
Yearend
Sammanfattning av delårsrapporten - fjärde kvartalet 2020 Under fjärde kvartalet meddelade Ziccum att en pilotstudie på storskalig produktion av temperaturstabila vacciner har genomförts. Pilotstudien avser en Fill and finish-anläggning...
25 January, 2021
News
IR
English
Regulatory
MAR
Corporate Action
Other
Lund, January 25, 2021 -- Ziccum AB (publ) (‘Ziccum’) entered into an evaluation study agreement on 3 Oct 2019 with Janssen Vaccines & Prevention B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Based on positive...
25 January, 2021
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
Lund, 25 januari 2021. Ziccum AB (publ) (‘Ziccum’) ingick ett utvärderingsavtal 3 oktober 2019 med Janssen Vaccine & Prevention B.V., en av Janssens läkemedelsbolag som tillhör Johnson & Johnson. Baserat på de...
01 December, 2020
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Action
Other
Ziccum AB (”Ziccum” eller ”Bolaget”) meddelar att handeln av Bolagets aktie på Nasdaq First North Growth Market inleds i dag under kortnamn ”ZICC” med ISIN SE0011415595. Göran Conradson, VD, kommenterar...
16 November, 2020
News
IR
English
Regulatory
Listing Regulation
Corporate Action
Other
Ziccum AB will be delisted from Spotlight after close of the market on November 30, 2020. For more information, see the press release from the company. Information about the share: Shortname: ZICC ISIN-code: SE0011415595 Orderbook-ID: 4NG9 CFI...
11 November, 2020
News
IR
English
Regulatory
LHFI
Corporate Action
Other
Ziccum AB ("Ziccum" or "the Company") announces today, November 11, 2020, that it has received approval for admission to trade on the Nasdaq First North Growth Market. The first day of trading on the Nasdaq First North Growth Market...
11 November, 2020
News
IR
Swedish
Regulatory
LHFI
Corporate Action
Other
Ziccum AB ("Ziccum" eller "Bolaget") har idag den 11 november 2020 erhållit godkännande för upptagande till handel på Nasdaq First North Growth Market. Första dag för handel på Nasdaq First North...
06 November, 2020
News
IR
Swedish
Regulatory
VPML
Report
Interim
Q3
Sammanfattning av delårsrapporten under tredje kvartalet 2020 Ziccum har under tredje kvartalet gjort stora framsteg i arbetet med att industrialisera sin unika process för att framställa vacciner i torr pulverform. Stora ekonomiska och...
06 November, 2020
News
IR
English
Regulatory
VPML
Report
Interim
Q3
Summary of interim report, third quarter 2020 During the third quarter Ziccum made great progress in its work of industrializing its unique process for producing vaccines in dry powder form. Major economic and production-technical advantages have been...